SEARCH:   Advanced

Blood, 15 November 2006, Vol. 108, No. 10, pp. 3450-3457. Prepublished online as a Blood First Edition Paper on June 1, 2006; DOI 10.1182/blood-2006-04-017749. This Article Full Text (PDF) All Versions of this Article: blood-2006-04-017749v1 108/10/3450    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dicker, F. Articles by Kipps, T. J. Search for Related Content PubMed PubMed Citation Articles by Dicker, F. Articles by Kipps, T. J. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 18, 2006 Accepted May 2, 2006 CD154 induces P73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional P53 Frank Dicker, Arnon P. Kater, Carlos E. Prada, Tetsuya Fukuda, Januario E. Castro, Guizhen Sun, Jean Y. Wang, and Thomas J. Kipps* MLL Munich Leukemia Laboratory GmbH, Munich, Germany Academic Medical Center, University of Amsterdam, the Netherlands Moores Cancer Center, University of California San Diego Tokyo Medical and Dental University, Tokyo, Japan Moores Cancer Center, University of California, San Diego Moores Cancer Center, University of California, San Dieg * Corresponding author; email: tkipps{at}ucsd.edu. Abstract Intravenous infusion of autologous chronic lymphocytic leukemia (CLL) cells transduced with an adenovirus encoding CD40-ligand (CD154) caused rapid reductions in leukemia-cell counts and lymph-node size. We hypothesized that CD40-ligation via CD154 sensitized CLL cells to death-receptor-mediated apoptosis. We found that CD154-expressing cells induced expression of CD95 and the BH3-interacting-domain death agonist (Bid) in CLL, regardless of whether the leukemia cells had functional p53. Such treatment also induced p73, a p53-related transcription factor regulated by c-Abl kinase, and enhanced the sensitivity to fludarabine (F-ara-A) of CLL cells lacking functional p53. Transduction of CLL cells with an adenovirus encoding p73 also induced Bid and CD95 and enhanced the sensitivity to F-ara-A of p53-deficient CLL cells. However, inhibition of c-Abl with imatinib suppressed CD154-induced expression of p73, p73-induced expression of Bid and CD95, and blocked the sensitization of p53-deficient CLL cells to CD95-mediated or F-ara-A-induced apoptosis. Conversely, CLL cells transduced with an imatinib-resistant c-Abl mutant could be induced by CD154 to express p73 and Bid even when treated with imatinib. These results indicate that CD154 can sensitize leukemia cells to apoptosis via the c-Abl-dependent activation of p73 and mitigate the resistance of p53-deficient CLL cells to anti-cancer drug therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. P. Kater, M. H. J. van Oers, and T. J. Kipps Cellular immune therapy for chronic lymphocytic leukemia Blood, October 15, 2007; 110(8): 2811 - 2818. [Abstract] [Full Text] [PDF] S. Willimott, M. Baou, S. Huf, S. Deaglio, and S. D. Wagner Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4 Haematologica, October 1, 2007; 92(10): 1359 - 1366. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020